Translational Takeaways: May 17, 2026

This week’s dermatology literature highlighted an increasingly important theme across inflammatory and procedural care: outcomes are being shaped not only by new therapeutics, but also by how clinicians optimize patient experience, timing of diagnosis, and individualized treatment strategy.

Procedural Experience Becomes a Clinical Variable

A prospective controlled study evaluating auditory distraction during cosmetic botulinum toxin injections suggests that simple environmental modifications may meaningfully improve procedural tolerability, particularly in treatment-naïve patients.¹

Both patient-selected music and standardized white noise reduced procedural pain compared with routine clinic sound exposure:

• Mean pain scores:
  • Control: 6.80
  • Music: 5.70
  • White noise: 5.52

The effect appeared most pronounced among first-time botulinum toxin patients, who otherwise reported significantly higher pain scores than experienced patients.

Notably, nearly all participants favored continuing sound interventions during future procedures:

• 85% in the music group
• 96.8% in the white noise group

Translationally:

As aesthetic dermatology becomes increasingly experience-driven, low-cost sensory interventions may emerge as practical tools for improving procedural tolerability and patient retention—especially among anxious or first-time cosmetic patients.

The findings also reinforce a broader point increasingly relevant in procedural dermatology: anxiety modulation itself may meaningfully influence pain perception.

MORE IN AESTHETICS

Hidradenitis Suppurativa: Weight Loss Alone May Not Fully Predict Outcomes

A cross-sectional Saudi Arabian study evaluating bariatric surgery in HS found numerically lower pain, depression, anxiety, and quality of life impairment among patients who had undergone surgery—but none of these differences remained statistically significant after adjustment.²

Even so, several trends persisted:

• Lower mean DLQI scores
• Lower PHQ-9 and GAD-7 scores
• Lower pain scores in post-bariatric patients

Pain severity demonstrated the strongest correlation with impaired quality of life and psychological burden.

Translationally:

The findings reinforce that obesity reduction may represent only one component of HS disease modification. Persistent scarring, chronic pain, excess skin folds, and postoperative nutritional changes may all continue to influence disease burden even after substantial weight loss.

Clinically, the study further supports pain assessment as a practical surrogate marker for broader psychosocial impairment in HS management.

MORE ON HS

HS Diagnosis Itself Appears to Change the Care Trajectory

A large retrospective analysis from the Premier Health care Database found that patients with formally diagnosed HS experienced substantially earlier biologic initiation and lower acute healthcare utilization than patients with suspected but undiagnosed disease.³

Among adults:

• Time to biologic initiation:
  • Confirmed HS: 109.8 days
  • Suspected HS: 165.5 days
• 30-day hospitalization risk:
  • Confirmed HS: 0.8%
  • Suspected HS: 3.7%
• ED visit risk:
  • Confirmed HS: 2.6%
  • Suspected HS: 11.7%

However, disparities persisted:

• Hispanic and Black patients experienced longer delays to biologic initiation
• Higher social vulnerability index scores were associated with delayed care access

Translationally:

The data suggest that earlier recognition of HS may itself alter downstream utilization patterns, accelerating access to multimodal management while reducing high-acuity healthcare use.

At the same time, the persistence of racial and socioeconomic disparities indicates that diagnostic recognition alone is unlikely to eliminate treatment-access inequities.

Psoriasis: Therapeutic Drug Monitoring Moves Closer to Precision Dermatology

A large PK/PD modeling study evaluating adalimumab in psoriasis suggests proactive therapeutic drug monitoring (TDM) could potentially improve biologic outcomes while identifying patients unlikely to benefit from continued dose escalation.⁴

Simulation modeling showed:

• PASI90 rates improved from 28.3% to 38.9% using proactive TDM-guided adjustments
• PASI75 rates improved from 62.4% to 70.4%

The study also identified distinct patient subsets:

• Patients with persistently low trough levels despite escalation were less likely to achieve PASI90
• Some well-controlled patients maintained response despite simulated dose de-escalation

Translationally:

While still modeling-based rather than prospective interventional evidence, the study reflects growing momentum toward PK/PD-guided biologic optimization in dermatology.

Rather than relying solely on empiric escalation or switching, future psoriasis management may increasingly incorporate serum drug exposure, immunogenicity, and individualized response prediction into routine decision-making.

Chronic Spontaneous Urticaria: Autologous IgG Therapy Explores an Immunomodulatory Approach

A small prospective pilot study evaluating intramuscular autologous total IgG injections in antihistamine-refractory CSU demonstrated improvements in disease activity, symptom control, and quality of life over 24 weeks.⁵

Key findings included:

• Median UAS7 improvement: −13 points
• Median UCT improvement: +4 points
• 27.3% of patients completing follow-up achieved complete remission (UAS7=0) at Week 24

No serious adverse events were reported.

Translationally:

Although preliminary and uncontrolled, the persistence of benefit beyond the active treatment period raises interest in whether autologous IgG therapy may exert broader immunomodulatory effects rather than transient symptomatic suppression alone.

Larger controlled studies will ultimately determine whether this approach can evolve beyond experimental use.

MORE ON CSU

References

1. Ozgen Z. Do White noise or music relieve pain caused by botulinum toxin injections?. Pain Res Manag. 2026;2026(1):e3007685. doi:10.1155/prm/3007685
2. Alsukait S, Alotaibi H, Alkofide M, et al. Impact of bariatric surgery on quality of life and psychological well-being among patients with hidradenitis suppurativa: a cross-sectional study. Clinical, Cosmetic and Investigational Dermatology, 19. 2026. doi:10.2147/CCID.S584656
3. Chovatiya R, Gayle J, Low R, Oh T, Gomez I, Rosenthal N. Patient journey and disparities in the diagnosis and treatment of patients with hidradenitis suppurativa. JIDInnov . 2026;6(3):100462. Published 2026 Feb 24. doi:10.1016/j.xjidi.2026.100462
4. Pan S, Tsakok T, Wei R, et al. Evaluation of a therapeutic drug monitoring strategy for adalimumab in psoriasis: a prospective pharmacokinetic-pharmacodynamic study. ClinTransl Sci . 2026;19(5):e70563. doi:10.1111/cts.70563
5. Ye YM, Kim ME, Kwon B, Nahm DH. Clinical efficacy and safety of intramuscular injections of autologous total IgG in patients with chronic spontaneous urticaria: an open-label prospective pilot trial. Exp Dermatol. 2026;35(4):e70249. doi:10.1111/exd.70249